Chronic Spontaneous Urticaria: Omalizumab Therapy & Clinical Management

Clinical Overview

Chronic spontaneous urticaria (CSU) is defined by the presence of wheal and/or angioedema occurring on most days (≥4 days per week) for at least 6 weeks, without an identifiable trigger in most patients. This differs from acute urticaria, which is typically self-limited and lasts <6 weeks. CSU affects approximately 0.5-1% of the population and has a female predominance (1.5-2:1), with peak incidence in the fourth to fifth decade of life. The condition significantly impacts quality of life, with studies demonstrating DLQI scores comparable to severe psoriasis or atopic dermatitis.

Epidemiology & Risk Factors

The prevalence of CSU is approximately 0.5-1% globally, though studies suggest it may be underdiagnosed. Key epidemiological features include female predominance and peak presentation between ages 40-60 years. Importantly, unlike acute urticaria, CSU is not allergic in the majority of patients—only 5-10% have identifiable specific allergens. Risk factors include:

• Autoimmune conditions: 30-40% of CSU patients have anti-IgE or anti-FcεRI antibodies (detected by basophil activation test or skin biopsy)
• Thyroid disease: Present in up to 20% of CSU patients; routine thyroid screening is recommended
• Helmintic infections (in endemic regions)
• Genetic predisposition: HLA associations noted in some populations

Pathophysiology

CSU involves mast cell activation and degranulation leading to histamine release. The pathophysiology encompasses multiple mechanisms:

• Autoimmune pathway: Anti-IgE antibodies or anti-FcεRI receptor antibodies in 30-40% of patients activate mast cells via crosslinking of high-affinity IgE receptors
• Direct mast cell activation: Infections (particularly Helicobacter pylori), medications (NSAIDs, ACE inhibitors), and other triggers directly activate mast cells
• Complement pathway: C5a-mediated mast cell activation in some patients
• Histamine-mediated effects: H1 and H2 receptor activation causes vasodilation, plasma extravasation, and flare reactions; H1 activation mediates pruritus and wheal formation

The dysregulation of mast cell function is central to all CSU pathways. Tryptase levels may be elevated in mast cell activation disorders, though routine tryptase measurement is not recommended in typical CSU.

Clinical Presentation & Classification

CSU presents with recurrent wheals (urticaria) and/or angioedema occurring on at least 4 days per week for ≥6 weeks. Wheals are transient (resolve within 24 hours, unlike urticarial vasculitis) and pruritic erythematous papules or plaques. Angioedema is deeper subdermal/mucosal swelling, often involving lips, tongue, throat, hands, and genitalia, and typically lasts 24-72 hours.

Urticaria activity score (UAS7): Total weekly score ≥16 indicates inadequate control on standard H1 antihistamines; this validated metric guides treatment escalation. IgE-mediated CSU should be distinguished from physical urticarias and urticarial vasculitis through careful history and examination.

Diagnosis & Workup

Diagnosis of CSU is clinical, based on the characteristic history. Recommended workup includes:

• Clinical history and examination to rule out physical urticarias (cold, pressure, vibration, solar, aquagenic) and drug-induced causes
• Complete blood count and comprehensive metabolic panel to exclude systemic disease
• Thyroid stimulating hormone (TSH) and thyroid peroxidase antibodies (TPO) given high prevalence of thyroid disease
• Testing for specific allergens only if directed by history (not routine screening)
• Basophil activation test (BAT) or autologous serum skin test (ASST) may identify autoimmune CSU but are not required for diagnosis or treatment decisions
• Skin biopsy only if the lesions appear atypical or are non-blanching, to exclude urticarial vasculitis or other diagnoses

Extensive allergy testing is not recommended and delays appropriate treatment.

Treatment Algorithm

Step 1: First-Line Therapy

Second-generation H1-antihistamines at standard approved doses:

• Cetirizine 10 mg daily
• Fexofenadine 180 mg daily
• Loratadine 10 mg daily
• Desloratadine 5 mg daily

Second-generation antihistamines are preferred over first-generation (diphenhydramine, hydroxyzine) due to reduced sedation and anticholinergic effects. Approximately 40-50% of CSU patients achieve control with standard-dose second-generation H1 antihistamines.

Step 2: Escalation—High-Dose Antihistamines

For patients with inadequate response at 4-6 weeks, increase to up to 4-fold the standard dose:

• Cetirizine 40 mg daily (10 mg four times daily)
• Fexofenadine 720 mg daily (180 mg four times daily)
• Desloratadine 20 mg daily (5 mg four times daily)

Approximately 50-60% of patients achieve control with high-dose antihistamines. Continue for 2-4 weeks before escalating. QTc monitoring is recommended with desloratadine at very high doses, though risk is low.

Step 3: Add Omalizumab

For patients inadequately controlled on high-dose antihistamines, add omalizumab, a recombinant anti-IgE monoclonal antibody. Dosing is weight-based:

• 150-375 mg subcutaneously every 4 weeks (exact dose determined by baseline IgE level and body weight)

The ASTERIA II trial demonstrated ASST 50 (≥50% reduction in wheal count on auto serum skin testing) in 67% of omalizumab-treated vs 5% of placebo patients; complete urticaria control was achieved in 32% of omalizumab-treated vs 2% placebo. Efficacy typically increases over 3-6 months. Omalizumab is highly effective in both IgE-mediated and autoimmune CSU.

Step 4: Cyclosporine or JAK Inhibitors

For patients who fail omalizumab:

• Cyclosporine: 1-5 mg/kg/day in divided doses. Requires monitoring of renal function and blood pressure every 2-4 weeks. Response rates of 60-80% reported. Monitor trough levels and long-term use is limited due to nephrotoxicity and hypertension risk.
• JAK inhibitors: Baricitinib 2-4 mg daily is emerging as a promising option with favorable efficacy in clinical trials and better tolerability than cyclosporine.

Prognosis & Complications

Spontaneous remission rates in CSU are 20-30% per year. Approximately 50% of patients remit within 5 years, though some cases persist for decades. The primary complication is angioedema involving the airway, which is rare but life-threatening and necessitates urgent access to epinephrine. Secondary complications include sleep disruption, depression, and anxiety due to chronic symptoms and unpredictability.

Anaphylaxis is not typical of CSU; if patients experience systemic symptoms (hypotension, syncope, respiratory distress), alternative diagnoses must be considered.

When to See a Dermatologist

Referral to dermatology is indicated for:

• Initial diagnosis confirmation, particularly if presentation is atypical
• Management of inadequate response to standard antihistamines
• Initiation and monitoring of omalizumab, cyclosporine, or other advanced therapies
• Exclusion of physical urticarias or urticarial vasculitis
• Evaluation of concurrent angioedema affecting airway or requiring specialist assessment

Frequently Asked Questions

Why did my chronic urticaria develop and can it be cured?

The exact trigger for CSU development is unknown in most patients, which is why it is called "spontaneous" urticaria. Unlike acute urticaria (often food or medication-triggered), CSU is rarely due to a persistent allergen. About 30-40% of CSU is autoimmune in nature (caused by antibodies against IgE or its receptor), while other cases involve mast cell dysfunction or are associated with infection or thyroid disease. Cure depends on the underlying mechanism: some patients remit spontaneously (20-30% annually), while others require long-term therapy. Modern treatments like omalizumab control disease activity in the majority of patients, even if the underlying cause persists.

Is extensive allergy testing necessary for chronic urticaria?

No. Extensive allergy testing (skin prick tests, specific IgE testing) is not recommended in CSU because most CSU is not IgE-mediated. Testing is only indicated if the patient's history suggests a specific trigger (e.g., always occurs after peanut ingestion). Unnecessary testing delays diagnosis and appropriate treatment initiation. The focus should be on ruling out physical triggers through directed history and optimizing medical therapy.

What should I do if I develop throat swelling or difficulty breathing?

Throat or airway swelling (angioedema of the larynx) is rare in typical CSU but is a medical emergency. If you experience throat tightness, difficulty swallowing, stridor (high-pitched breathing sounds), or difficulty breathing, call emergency services (911 in the US) immediately. Ask your dermatologist if you should carry an epinephrine auto-injector (EpiPen) as a precaution, particularly if angioedema is part of your symptom pattern.

How long will I need to take antihistamines, and can I stop abruptly?

The duration of therapy depends on your disease course. Some patients achieve long-term remission and can discontinue medication; others require continuous therapy. Do not stop antihistamines abruptly—rebound or disease exacerbation can occur. If you are considering discontinuation after a period of good control, discuss a gradual taper plan with your dermatologist. The goal is to use the lowest effective dose long-term and periodically reassess the need for therapy.

References